Analysts Expect Teladoc Health Inc (NYSE:TDOC) Will Announce Quarterly Sales of $129.66 Million

Wall Street brokerages predict that Teladoc Health Inc (NYSE:TDOC) will announce sales of $129.66 million for the current quarter, Zacks Investment Research reports. Ten analysts have issued estimates for Teladoc Health’s earnings. The lowest sales estimate is $128.90 million and the highest is $130.11 million. Teladoc Health reported sales of $94.56 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 37.1%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that Teladoc Health will report full year sales of $541.11 million for the current financial year, with estimates ranging from $537.20 million to $543.94 million. For the next financial year, analysts anticipate that the firm will report sales of $681.50 million, with estimates ranging from $662.70 million to $752.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Teladoc Health.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Tuesday, April 30th. The health services provider reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.01. The business had revenue of $128.57 million for the quarter, compared to analyst estimates of $127.99 million. Teladoc Health had a negative return on equity of 10.86% and a negative net margin of 22.63%. The company’s quarterly revenue was up 43.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.39) EPS.

A number of brokerages have weighed in on TDOC. ValuEngine upgraded Teladoc Health from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Bank of America began coverage on Teladoc Health in a research note on Thursday, June 13th. They issued a “buy” rating and a $65.00 target price on the stock. Zacks Investment Research upgraded Teladoc Health from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Craig Hallum restated a “buy” rating and issued a $70.00 target price (down from $80.00) on shares of Teladoc Health in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $70.00 target price on shares of Teladoc Health in a research note on Tuesday, April 30th. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $82.68.

In related news, CEO Jason N. Gorevic sold 30,000 shares of the stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $53.04, for a total transaction of $1,591,200.00. Following the completion of the sale, the chief executive officer now directly owns 673,924 shares in the company, valued at approximately $35,744,928.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Andrew Turitz sold 31,960 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $55.82, for a total value of $1,784,007.20. Following the sale, the senior vice president now owns 13,455 shares of the company’s stock, valued at $751,058.10. The disclosure for this sale can be found here. Insiders have sold a total of 144,542 shares of company stock worth $8,285,951 over the last quarter. Corporate insiders own 3.95% of the company’s stock.

A number of hedge funds have recently modified their holdings of TDOC. Janus Henderson Group PLC lifted its holdings in Teladoc Health by 87.2% in the 1st quarter. Janus Henderson Group PLC now owns 2,989,090 shares of the health services provider’s stock worth $166,197,000 after buying an additional 1,391,969 shares during the period. Vanguard Group Inc lifted its holdings in Teladoc Health by 26.9% in the 3rd quarter. Vanguard Group Inc now owns 5,874,182 shares of the health services provider’s stock worth $507,236,000 after buying an additional 1,244,388 shares during the period. Norges Bank purchased a new stake in Teladoc Health in the 4th quarter worth approximately $32,112,000. Macquarie Group Ltd. lifted its holdings in Teladoc Health by 101.5% in the 4th quarter. Macquarie Group Ltd. now owns 1,125,275 shares of the health services provider’s stock worth $55,780,000 after buying an additional 566,839 shares during the period. Finally, Bellevue Group AG lifted its holdings in Teladoc Health by 83.1% in the 4th quarter. Bellevue Group AG now owns 1,073,839 shares of the health services provider’s stock worth $53,230,000 after buying an additional 487,319 shares during the period.

Shares of NYSE TDOC opened at $66.22 on Friday. The company has a market cap of $4.50 billion, a price-to-earnings ratio of -45.99 and a beta of 1.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 7.54 and a quick ratio of 7.54. The business has a 50-day simple moving average of $59.71. Teladoc Health has a twelve month low of $42.08 and a twelve month high of $89.05.

About Teladoc Health

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Recommended Story: How are capital gains distributions different for tax-deferred account?

Get a free copy of the Zacks research report on Teladoc Health (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.